Long-term performance of closed cell design self-expanding stainless steel stents in the treatment of Cockett's Syndrome

Luís Loureiro, Rui Machado, Tiago Loureiro, Diogo Silveira, Sérgio Teixeira, Duarte Rego, Vítor Ferreira, João Goncalves, Gabriela Teixeira, Inês Antunes, Rui Almeida

Angiology and Vascular Surgery Department
Santo Antonio Hospital, Porto, Portugal
Disclosure

Speaker name:

Luís Loureiro

I do not have any potential conflict of interest
Long-term stent performance in Cockett’s

54y male PTS
CT venous angiogram
Contrast-dye injected in left foot
Long-term stent performance in Cockett’s

• Methods
  – Review clinical and imaging records of first 10 stents implanted in the left iliac veins at our center
  – Venous claudication and/or non-healing ulcer despite compression stockings
Long-term stent performance in Cockett’s

Cook Medical Launches World’s First Stent Engineered Specifically for Use in the Iliofemoral Veins

SEPTMBER 9TH, 2011

Tags: cook medical job loss medical device excise tax

Munich, Germany – Cook Medical, a world leader in minimally invasive medical technologies, has launched the world’s first-ever stent designed and approved specifically to treat symptomatic iliofemoral venous outflow obstruction. The Zilver Vena Venous Self-Expanding Stent has received CE Mark approval and is now available to physicians across Europe.

Long-term stent performance in Cockett’s

Ms. Sherry L. Sparrow
Regulatory Affairs Manager
Boston Scientific Scimed, Inc.
One Scimed Place
Maple Grove, MN 55311-1566

Re: P980033
WALLSTENT® Venous Endoprosthesis with Unistep™ Plus RP Delivery System
(10 mm Venous Endoprosthesis)
WALLSTENT® Venous Endoprosthesis with Unistep™ Plus Delivery System
(12 mm – 16 mm Venous Endoprostheses)
Filed: August 3, 1998
Amended: October 8 and November 27, 1998, March 25 and October 5, 1999, January 3
and 10, and June 29, 2000 and November 16, 2001

WALLSTENT Venous Endoprosthesis is indicated for:

• Improving central venous luminal diameter following unsuccessful angioplasty in patients on chronic hemodialysis with stenosis of the venous outflow tract.
• The vessels that can be treated with the WALLSTENT Venous Endoprosthesis are the innominate and subclavian veins, ranging from 8mm to 15mm in diameter

Long-term stent performance in Cockett’s

• Results
  – 7 patients (6 women)
  – mean 40.5 years-old (25-72)
  – Treated from 2004 to 2007
  – 1 stent – five patients
  – 2 stents – one patient
  – 3 stents – one patient
    • (2 primary treatment, 3rd in re-intervention)
Long-term stent performance in Cockett’s
Long-term stent performance in Cockett’s

• Results
  – 3 months anticoagulation
  – Life-long aspirin
  – Life-long compression stockings
  – 3 months, after yearly
    • X-Ray
    • Venous Doppler Enhanced Ultrasound
Long-term stent performance in Cockett’s
Long-term stent performance in Cockett’s

• Results
  – Follow-up
    • Mean 107 months (88-148)
    • Primary patency rate at 1 year: 86%
    • Primary assisted patency rate at 8 years: 100%
    • Stent fracture: 0%
    • Mortality: 0%
Long-term stent performance in Cockett’s
Long-term stent performance in Cockett’s
Long-term stent performance in Cockett’s
Long-term stent performance in Cockett’s Venography 1st patient 10 years follow-up
Long-term stent performance in Cockett’s

• The Wallstent™ Endoprosthesis was never approved in the European Community for the treatment of iliac veins obstruction.

• Nevertheless, our center experience shows that the device performs flawlessly in this sector.
Long-term stent performance in Cockett’s